BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sinagra E, Morreale GC, Mohammadian G, Fusco G, Guarnotta V, Tomasello G, Cappello F, Rossi F, Amvrosiadis G, Raimondo D. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017; 23(36): 6593-6627 [PMID: 29085207 DOI: 10.3748/wjg.v23.i36.6593] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Santucci NR, Saps M, van Tilburg MA. New advances in the treatment of paediatric functional abdominal pain disorders. Lancet Gastroenterol Hepatol 2020;5:316-28. [PMID: 31859185 DOI: 10.1016/S2468-1253(19)30256-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
2 Vahora IS, Tsouklidis N, Kumar R, Soni R, Khan S. How Serotonin Level Fluctuation Affects the Effectiveness of Treatment in Irritable Bowel Syndrome. Cureus 2020;12:e9871. [PMID: 32968548 DOI: 10.7759/cureus.9871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Sinagra E, Utzeri E, Morreale GC, Fabbri C, Pace F, Anderloni A. Microbiota-gut-brain axis and its affect inflammatory bowel disease: Pathophysiological concepts and insights for clinicians. World J Clin Cases 2020; 8(6): 1013-1025 [PMID: 32258072 DOI: 10.12998/wjcc.v8.i6.1013] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
4 Dickson K, Malitan H, Lehmann C. Imaging of the Intestinal Microcirculation during Acute and Chronic Inflammation. Biology (Basel) 2020;9:E418. [PMID: 33255906 DOI: 10.3390/biology9120418] [Reference Citation Analysis]
5 Zhang F, Weng ZJ, Wu LY, Bao CH, Yang L, Zhao M, Wu HZ, Liu HR, Zhou CL. Etiology related irritable bowel syndrome animal models. Shijie Huaren Xiaohua Zazhi 2018; 26(30): 1772-1777 [DOI: 10.11569/wcjd.v26.i30.1772] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Theodorou V, Beaufrand C, Yvon S, Laforge G, Burmeister Y, Müller A, Seilheimer B, Bueno L, Eutamene H. The multicomponent medication Spascupreel attenuates stress-induced gut dysfunction in rats. Neurogastroenterol Motil 2020;32:e13798. [PMID: 32059072 DOI: 10.1111/nmo.13798] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Zhang Y, Wu XX, Li S, Wu JF, Han S, Lin ZJ, Ding SZ, Gong WJ. Peroxiredoxin 1 as an inflammatory marker in diarrhea-predominant and postinfectious irritable bowel syndrome. Neurogastroenterol Motil 2020;32:e13741. [PMID: 31613423 DOI: 10.1111/nmo.13741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chelimsky G, Simpson P, Zhang L, Bierer D, Komas S, Kalyanaraman B, Chelimsky T. Impaired Mitochondrial Bioenergetics Function in Pediatric Chronic Overlapping Pain Conditions with Functional Gastrointestinal Disorders. Pain Res Manag 2021;2021:6627864. [PMID: 34426756 DOI: 10.1155/2021/6627864] [Reference Citation Analysis]
9 Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, Petrovic G, Zivkovic V. Irritable bowel syndrome - from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2018;162:1-9. [PMID: 29358788 DOI: 10.5507/bp.2017.057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Mei L, Zhou J, Su Y, Mao K, Wu J, Zhu C, He L, Cui Y. Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol 2021;21:105. [PMID: 33663411 DOI: 10.1186/s12876-021-01693-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ghoshal UC. Marshall and Warren Lecture 2019: A paradigm shift in pathophysiological basis of irritable bowel syndrome and its implication on treatment. J Gastroenterol Hepatol 2020;35:712-21. [PMID: 32162356 DOI: 10.1111/jgh.15032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
12 Cai T, Wang X, Li B, Xiong F, Wu H, Yang X. Deciphering the synergistic network regulation of active components from SiNiSan against irritable bowel syndrome via a comprehensive strategy: Combined effects of synephrine, paeoniflorin and naringin. Phytomedicine 2021;86:153527. [PMID: 33845366 DOI: 10.1016/j.phymed.2021.153527] [Reference Citation Analysis]
13 Sinagra E, Rossi F, Raimondo D, Conoscenti G, Anderloni A, Guarnotta V, Maida M. Tenapanor for the treatment of irritable bowel syndrome with constipation. Expert Rev Clin Pharmacol 2020;13:473-9. [PMID: 32478632 DOI: 10.1080/17512433.2020.1762570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Uno Y. Hypothesis: Mechanism of irritable bowel syndrome in inflammatory bowel disease. Med Hypotheses 2019;132:109324. [PMID: 31421429 DOI: 10.1016/j.mehy.2019.109324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Li Y, Yang T, Yao Q, Li S, Fang E, Li Y, Liu C, Li W. Metformin prevents colonic barrier dysfunction by inhibiting mast cell activation in maternal separation‐induced IBS‐like rats. Neurogastroenterology & Motility 2019;31:e13556. [DOI: 10.1111/nmo.13556] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Bin Waqar SH, Rehan A. Methane and Constipation-predominant Irritable Bowel Syndrome: Entwining Pillars of Emerging Neurogastroenterology. Cureus 2019;11:e4764. [PMID: 31363445 DOI: 10.7759/cureus.4764] [Reference Citation Analysis]
17 Zhang Y, Zhang L, Li S, Wu XX, Bi YX, Hu X, Chen YQ, Yuan Y. Serum levels of high sensitive C-reactive protein and tumor necrosis factor-alpha in different subtypes of irritable bowel syndrome and their correlation. Shijie Huaren Xiaohua Zazhi 2020; 28(16): 782-788 [DOI: 10.11569/wcjd.v28.i16.782] [Reference Citation Analysis]
18 Tait C, Sayuk GS. The Brain-Gut-Microbiotal Axis: A framework for understanding functional GI illness and their therapeutic interventions. Eur J Intern Med 2021;84:1-9. [PMID: 33423906 DOI: 10.1016/j.ejim.2020.12.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]